Positive functional results reported for aducanumab in a pooled, post hoc analysis

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Early Infusion of Mononuclear Cells May Benefit Stroke Patients

Publish date:: October 1, 2019

Key clinical point: Bone marrow mononuclear cells offer another promising cell therapy for early-stage treatment of ischemic stroke.

Major finding: Doses of bone marrow mononuclear cells up to 10 million cells/kg are well tolerated by patients within the first 72 hours post stroke.

Study details: A phase 1 study of 25 ischemic stroke patients.

Disclosures: The study was supported by grants from the National Institutes of Health. Dr. Savitz and many of his coauthors disclosed having numerous financial ties to the pharmaceutical and biotechnology industries.

Citation:

Vahidy F et al. Stem Cells. 2019 Sept. 17.

This Week's Must Reads

Health care: More uninsured as insurance costs grow faster,

Oral contraceptive use associated with smaller hypothalamic and pituitary volumes,

Intensive BP control reduced dementia but increased brain atrophy and hurt cognition,

Headache may be a significant outcome of pediatric hemispherectomy,

Parkinson’s patients can lose swimming ability after deep brain stimulation,

Must Reads in Stroke

Stroke is diagnosed in about one-fifth of children with strokelike symptoms,

Minimize blood pressure peaks, variability after stroke reperfusion,

Pediatric stroke thrombectomy study sheds light on off-label procedure,

Early Infusion of Mononuclear Cells May Benefit Stroke Patients,

Statins Reduce Risk of Early Poststroke Seizures,

Menu Close